Monoclonal Antibodies Pipeline | Precision-Engineered Reagents for Research and Diagnostics

Monoclonal Antibodies Pipeline

The pipeline offers a broad range of monoclonal antibodies for research and diagnostics, designed to support advances in immunology, oncology, and clinical applications. These reagents are designed for in vitro diagnostic (IVD) use or for research use only (RUO). All products are formulated under ISO13485 to ensure reliable and reproducible results, supporting researchers and healthcare professionals in achieving their scientific goals with confidence.

Blood group reagents are essential for determining blood types, ensuring safe transfusions, and preventing adverse reactions. Immune reagents, such as IgG subclasses and FLC, assist in diagnosing immune-related conditions. These precision-engineered tools enhance diagnostic accuracy, helping healthcare professionals tailor treatments and ultimately improve patient outcomes and safety.

There is a strong foothold in both local and international markets, catering to a wide range of sectors, including academic research institutions, pharmaceutical companies, and clinical laboratories. Its adaptive approach allows for success in the niche market of diagnostics, ensuring that reagents stay at the forefront of scientific advancements.

Monoclonal Antibodies Available for Testing

If you are interested in obtaining test samples from the monoclonal antibody pipeline, we encourage you to reach out to us. Our team is ready to discuss your project needs and provide you with the necessary samples for evaluation. We offer flexible sample quantities to accommodate both small-scale pilot projects and larger development phases.

Ensuring Quality and Reproducibility

All the monoclonal antibodies are produced under ISO13485-certified processes, ensuring they meet the highest standards of quality and reproducibility. You can trust that the samples you receive are optimized for reliable and consistent results in your laboratory, helping you move forward with confidence in your scientific endeavors.

For inquiries, you can contact us at order.handling@antibodychain.com

Monoclonal Antibodies Pipeline

Essange Reagents Antibody Table

Reference number Clone Antigen Isotype Buffer Specificity
M9050 CLB-12.8 ANCA IgG1 20 mM TRIS, 150 mM NaCI 80-100% positive with granulocytes
M9117 CLB-T1/1; 1C12 CD5 IgG1 20 mM Borat buffer + 150 mM NaCI 54-80% positive reaction with Lymphocytes
M9087 CLB-FcR gran/1; 5D2 CD16 IgG2a PBS + 0.1% NaN3 90-100% positive reaction with granulocytes
M9127 CLB-LFA1/1; 54 CD18 IgG1 20 mM TRIS, 150 mM NaCI 85-100% positive reaction with the lymphocytes
M9169 CLB-CD27/1; 9F4 CD27 IgG2a 20 mM TRIS, 150 mM NaCI 60% - 85% positive with lymphocytes
M9128 CLB-CD28/1; 15E8 CD28 IgG1 20 mM TRIS, 150 mM NaCI 50-75% positive reaction on PHA-stimulated lymphocytes
M9139 CLB-IVC7 CD36 IgG1 20 mM TRIS, 150 mM NaCI or 90-100% positive reaction with monocytes
M9049 CLB-gran/12; 435 CD63 IgG1 20 mM TRIS, 150 mM NaCI 70-100% positive reaction with activated platelets
M9146 CLB-gran/10; IH4Fc CD66acde IgG1 20 mM TRIS, 150 mM NaCI 95 to 100% positive with activated granulocytes
M9158 CLB-Ery1; AME-1 CD235a IgG1 20 mM TRIS, 150 mM NaCI 95 -100% positive with erythrocytes
M9196 GB12 Granzyme B IgG1 20 mM TRIS, 150 mM NaCI 8-25% positive with lymphocytes (cytoplasmatic)
M9105 MH16-1 IgG IgG1, kappa 20 mM TRIS, 150 mM NaCI Negative with lgG deficient serum
M9179 TNFα-7 TNF-alfa IgG1 20 mM TRIS, 150 mM NaCI Suitable as coat in TNF specific ELISA’s
M9089 CLB-MPO-1/1; 7.17 MPO IgG2a 20 mM TRIS, 150 mM NaCI 80 - 100% positive reaction with cytoplasmatic granulocytes
M9174 GB11 Granzyme B IgG1 20 mM TRIS, 150 mM NaCI 8-25% positive with lymphocytes (cytoplasmatic)
M9199 CLB-GA28 Granzyme A IgG1 20 mM TRIS, 150 mM NaCI (+0.09% (w/v) NaN3 as preservative) x
M9171 GB7 Granzyme B IgG2a 20 mM TRIS, 150 mM NaCI x
M9173 GB10 Granzyme B IgG1 20 mM TRIS, 150 mM NaCI x
M9261 4D1 Daratumumab IgG1, kappa PBS + 0.01% NaN3 x
M9262 8C3 Guselkumab IgG1, kappa PBS + 0.01% NaN3 x
M9263 1G11 Dupilumab IgG1, kappa PBS + 0.01% NaN3 x
M9264 7E9 Tocilizumab IgG1, kappa PBS + 0.01% NaN3 x
M9265 1C7 Vedolizumab IgG1, kappa PBS + 0.01% NaN3 x
M9023 CLB-T11.1/1 CD2 * * *
M9238 CLB-HIK27 CD2 * * *
M9243 CLB-thromb/8; 4E1 CD9 * * *
M9152 CLB-CALLA/1; 4F9 CD10 * * *
M9106 CLB-gran/11; 5D7 CD16b * * *
M9004 CLB-B4/1; 11G1 CD19 * * *
M9118 NKI-IH4 CD20 * * *
M9245 CLB-4D3; 5D1 CD21 * * *
M9005 CLB-B-Ly/1 CD22 * * *
M9246 CLB-gran-B-ly/1; IB5 CD24 * * *
M9178 CLB-22C3 CD26 * * *
M9145 CLB-MD33.6 CD33 * * *
M9096 CLB-MD34.2 CD34 * * *
M9107 CLB-ID5 CD38 * * *
M9119 CLB-tromb/7; 6C9 CD42b * * *
M9248 NKI-P2; P2 CD44 * * *
M9073 CLB-T200/1; 15D9 CD45 * * *
M9102 NKI-SAM-1 CD49e * * *
M9047 NKI-GoH3 CD49f * * *
M9236 NKI-M9 CD51 * * *
M9120 CLB-tromb/1; C17 CD61 * * *
M9206 CLB-2F2 CD70 * * *
M9153 FAS18 CD95 * * *
M9162 CLB-1D4 CD138 * * *
M9231 CLB-203; 5A497 Control IgG1 * * *
M9232 713 Control IgG2a * * *
M9200 CLB-GA29 Granzyme A * * *
M9204 CLB-GA6 Granzyme A * * *
M9159 MD5 IFN-gamma * * *
M9104 MH14-1 IgA * * *
M9177 MH25-1 IgE * * *
M9182 MH15-1 IgM * * *
M9209 IL-1β-8 IL-1-beta * * *
M9113 CLB-IL-4-1 IL-4 * * *
M9114 CLB-IL-4-5 IL-4 * * *
M9090 CLB-IL-6.16 IL-6 * * *
M9184 MH29-2 L-chain Lambda * * *
M9166 CLB-T3/4.E; 1XE CD3 IgE 50-85% positive with human Lymphocytes
M9125 CLB-T4/1; 10A12 CD4
* is not yet finalised as product, can be developed upon needs

For inquiries, you can contact us at order.handling@antibodychain.com